Introduction

47
For a vaccine to be regarded as effective, it must stimulate an adequate immune 48 response, sustain safe administration and be patient friendly [1, 2] . Subunit vaccines 49 contain selected purified antigens and potentially reduce side effects, eradicate 50 reversion to virulence and the need for culturing harmful pathogens, whilst eliciting 51 specific immune responses, ultimately generating a safer, more immunologically Liposome formulations were prepared by the long established method of lipid hydration 154 [18] . Lipids were dissolved in a chloroform:methanol mixture (9:1 v/v), with DDA and 155 TDB set to a 5:1 DDA:TDB weight ratio/8:1 molar ratio. Additional liposomal 156 formulations were prepared where this DDA:TDB remained locked at this ratio but 6 rotary evaporation and N2 flushing, a dry film was produced. The remaining film was 160 hydrated in Tris buffer (10 mM, pH 7.4) for 20 minutes at 10 °C above the main gel-to-161 liquid phase transition of DDA at ~47 °C [11, 19] or DSPC at 55 °C to completely 162 hydrate the film and form liposomes. Addition of H56 was performed after liposome 163 formation at final concentrations of 0.1 mg/mL. Antigen adsorption to liposomes was 164 promoted by incubation for 30 minutes at room temperature.
Materials and Methods
166
Determination of particle size and zeta potential by dynamic light scattering 167
The z-average diameter and zeta potential was measured using via dynamic light 168 scattering (DLS) (Malvern Zetasizer Nano-ZS, Malvern Instruments, Worcs., UK).
169
Measurements took place at 25 °C in (1/10 dilution; 1 mM TRIS, pH 7.4). All 170 measurements were carried out on triplicate batches of formulations.
172
Immunisation study 
270
INF-γ, IL-2, IL-5, IL-6, IL-10, spleen proliferation) was displayed in a loading plot, using 271 all experimentally obtained raw data in this study. Model fit was interpreted by 272 goodness of fit (R 2 ) and goodness of prediction (Q 2 ) and regarded as good for R 2 >0.5 9 Weights were selected to maximize the correlation. The loading scatter plot was used Upon vesicle production, dynamic light scattering was used to determine the particle 288 size, polydispersity and zeta potential of the liposomes before and after H56 antigen 289 addition (0.1 mg/mL: 5 µg/vaccine dose). In the present study, DDA-TDB remained 290 locked at a molar ratio of 8:1, as previous studies found this ratio to be most beneficial 291 in immunological performance [11] . This formulation was modified by the incorporation 292 of DSPC in substitution for DDA-TDB at various molar % ratios, therefore the 293 concentrations of DSPC, DDA and TDB were each varied but the DDA and TDB 294 concentrations were linked (Table 1) . From the results, it can be seen that varying the 295 composition of the liposomes resulted in changes in both vesicle size and zeta 296 potential ( Table 2 ). The particle size of DDA-TDB liposomes in Tris buffer prior to 297 substitution was ~500 nm, with a polydispersity of 0.3 and a strong cationic surface 298 charge of ~50 mV (Table 2 ), in accordance with previous results [11, 19, 20] .
299
Incorporation ofDSPC generated significantly larger vesicles (P < 0.05) but with no 300 clear trend of DSPC concentration to vesicle size and all remained in a sub micrometer 301 size range of 650-850 nm. In contrast the zeta potential decreasing with increasing 302 DSPC, as would be expected (Table 2) . Upon surface adsorption of H56 antigen the 303 particle size of all formulations increased significantly (P < 0.05) to 850 -1300 nm 304 depending on the formulation, whilst cationic zeta potential decreased ( 
310
Immunological characterization for H56 specific antibody isotypes 311 10 When considering the antibody responses in mice immunised, by day 37 all four of the 312 liposome formulations induced significantly higher (P < 0.05) IgG immune responses 313 in mice compared to mice immunised with antigen alone, with no significant difference 314 between the formulations (Fig. 1A) . A similar trend was noted with IgG1 responses in 315 the vaccinated mice ( Fig. 1B) . In the case of IgG2b (Fig. 1C ), liposomal adjuvants 316 composed of 75 mol% DSPC generated significantly lower (P < 0.05) levels of antibody 317 titres at all time points tested compared to DDA-TDB, and IgG2b responses were not 318 significantly different to responses in mice immunised with non-adjuvanted H56 (Fig.   319   1C ). This suggests that up to 50 % DSPC within the liposome formulation did not 
329
Immunological characterization for H56 specific spleen proliferation rates 330 Antigen specific splenocyte proliferation in mice previously vaccinated with the 331 liposomal systems and upon re-stimulation with H56 vaccine at increasing 332 concentrations from 0-25 μg/mL was assessed. DDA-TDB liposomal adjuvants 333 generated the strongest cell proliferation (Fig. 2) . However, cell proliferation was seen 334 to be dependent on DDA-TDB concentration as there is a notable trend of decreasing 335 responses from cells harvested from mice immunised with liposomes containing 336 increasing DSPC levels (and corresponding decreasing levels of DDA-TDB) within the 337 liposome formulation (Fig. 2) . Indeed, liposomal adjuvants containing 75 mol% DSPC 338 were consistently low even upon re-stimulation at higher H56 concentrations (Fig. 2) .
340
Spleen cell cytokine responses 341 Spleen cell cytokine responses from mice immunised with the various liposomal 342 formulations show variable correlation to the DSPC content (Fig. 3) . In general, IFN-343 γ, IL-2 and IL-6 levels were shown to decrease with increasing DSPC content (Fig. 3A, 
344
B and D). Whilst IL-5 production was low for all groups (Fig. 3C) , with mice which 345 received antigen alone having similar levels to those mice which received liposomal 346 adjuvants. In contrast, the presence of DSPC in the liposomal adjuvant tended to 347 increase IL-10 responses (Fig 3E) .
349 11
With increasing replacement of DDA-TDB with DSPC in the formulation, the zeta 350 potential decreases and the strength of immune response tends to skew towards a 351 Th2 type response, even with the small decreases in zeta potential noted in these 352 formulations (Table 1) . The effect of liposomal charge has been studied previously for 353 the quality of immunity stimulated with Ag85B-EAST-6 antigen [20] in which it was 354 noted that production of IFN-γ was strongly dependent upon the liposomal adjuvants 
379
In the second analysis study, we selected the liposome size, zeta potential and DDA 380 concentration as variables (3 X-variables and 9 Y-variables). Obviously, given that zeta 381 potential measurements are be directly linked to the amount and type of lipid used (as 382 well as the aqueous media the liposomes are suspended in), the zeta potential 383 represents a response towards lipid composition. However, this set allowed us to verify 384 how the model predicted the influence of zeta potential on immune responses in-vivo.
385
Here, the cumulative goodness of fit was 0.97 and the goodness of prediction was 386 0.52, with two PC fitted (PC1 with 64% of the fraction in the X-variation modelled 12 (eigenvalue 1.92), 97% respectively in the PC2 (eigenvalue of 0.98); Y-variation 388 modelled in first PC was 44%, 53% in PC2). Unfortunately, including the TDB 389 concentration as a variable resulted in a non-statistically valid model.
390
PC1 and PC2 in both model setups were regarded to comprise satisfactory information 391 to construct a predictive model on the data set. Furthermore, we analysed the 392 cumulated R 2 and Q 2 values for each Y-variable (Fig. 4 ), in both model setups. R 2 393 represents a goodness of the model fit and describes how well the variation of the 394 respective variable is explained; Q 2 indicates how well the respective variable can be 395 predicted. A threshold value for R 2 > 0.5 was chosen for valid models; values below 0.5 396 indicated noise present. IgG and IgG1 responses were shown to be insignificant in 397 both designs chosen, due to negative Q 2 value ( Fig. 4 A and B) . Spleen proliferation,
398
INF-γ, IL-2, and IL-6 showed good model fit above 0.5, with respective good prediction 399 power indicated by a relatively low level of noise in the data set ( Fig. 4 A and B ).
400
Goodness of prediction for the responses IgG2b, IL-5 and IL-10 was at or below 0.5,
401
indicating a higher amount of noise present for these responses.
402
PLS regression to cluster H56 specific antibody isotypes 403
Modelling of the data revealed no strong or moderate outliers present (evaluated in the 404 PCA analysis; data not shown). Due to insignificance in the model for the antibody 405 subtypes IgG and IgG1, these were removed from further analysis, with IgG2b 406 remaining, but at a low confidence level. This is in line with the basic statistical analysis 407 in Figure 1 that revealed no significant difference between the formulations for IgG and 408 IgG1, confirming that these antibody subtypes are not an ideal measure for vaccine 409 efficacy in these systems, indicated by statistical insignificance in the PLS analysis.
411
PLS regression to analyse specific spleen proliferation rates 412
The liposomal adjuvants were shown to promote splenocyte proliferation upon 413 restimulation with H56 antigen, demonstrated by the strong correlation between the 414 variables DDA (Fig. 4C) (and zeta potential; Fig. 4D ) to splenocyte proliferation in the 415 coefficient plot, with size not shown to correlate with responses. DDA concentration is 416 the most influential variable for the response spleen proliferation, visible by the high 417 coefficient value (close to 1) as well as a small confidence interval. The loading scatter 418 plots shows a close correlation of splenocyte proliferation response to the variable 419 DDA (Fig. 4E ) and zeta potential (Fig. 4F ), identifying their strong correlation. This 420 confirms that the biggest effect to spleen proliferation rates is the increase in DDA 421 content, which is strongly linked to the zeta potential of a vaccine. As indicated in 422 Figure 3 , the peak of proliferation correlates with DDA-TDB liposomes, which have the 423 strongest zeta potential (Table 2) . The PLS analysis revealed a statistical significance for the responses INF-γ, IL-2, IL-6 427 and IL-10 for the variables DDA ( Fig. 4 C) , as well as for the variable zeta potential 428 ( Fig. 4D ) again as would be expected due to their link. Overall, the DDA content as 429 well as the zeta potential showed a positive correlation to INF-γ, IL-2 and IL-6, and an 430 inverse correlation to the response IL-10. The increase in DDA in a vaccine adjuvant 431 formulation gave no notable correlation in size but does result in a higher zeta potential, 432 which is predicted to increase the specific INF-γ, IL-2 and IL-6 production in-vivo. The 433 corresponding peak in INF-γ production (Fig. 3A) was detected for the DDA-TDB 434 liposomes, which also provided the strongest cationic zeta potential (Table 2) . Here, 435 the model predictions are in line with the previous reported results that showed 436 increasing cationic charge (but with constant TDB concentrations across the 437 formulations) enhanced INF-γ as well as . However in addition to this, the 438 model suggests no impact of DDA and zeta potential content on IL-5, but an inverse 439 correlation between the response IL-5 and the liposome size ( Fig. 4C and D) , indicating 440 that a smaller liposome size is predicted to increase the specific IL-5 production. 
445
The specific regression coefficients ( Fig. 4E and F) We see that the DDA (and the linked TDB) concentration in a vaccine formulation is a 463 crucial variable and most importantly more influential to the immunological response 464 than the actual liposome size (across the range considered). Generally, a strong link 465 between the DDA concentration and zeta potential could be identified; for selecting the 466 zeta potential as a Y-response ( Fig. 4E ) as well as a X-variable ( Fig. 4F) , its close link 467 to DDA as a variable confirms the significance of the zeta potential to initiating a Th1 468 mediated immune response in-vivo. Overall, the model developed was statistically 469 valid for the variables, DDA and zeta potential (spleen proliferation, IFN-γ, IL-2, IL-6, 470 IL-10, IgG2b), and to limited extent liposome size (in the case of IL-5), as summarized 471 by the importance of the x-variables. The variable influence on projection plot (VIP) 472 ( Fig. 5) , which summarizes all components and y-variables [23] , indicated that the 473 variable DDA content ( Fig. 5A ) and zeta potential (Fig. 5A&B) were ranked as the 474 variables with the highest impact in the PLS models. However, whilst the zeta potential 475 is shown to strongly influence the immune responses in-vivo and thus could be taken 476 as a controlling factor, it is directly linked to the DDA content. Furthermore, we have 477 previously shown that liposomes of the same DDA content, and hence same zeta 478 potential, gave different immunological profiles depending on the TDB content [11] .
479
This demonstrates that controlling factors between the formulation and the physico-480 chemical characteristics must be identified when applying MVA to avoid incorrect 481 interpretation.
483
Model validation 484
To assess the validity of the predictions made by the PLS analysis, the model was 485 validated using respective permutations plots for each specific Y-response ( Fig. 6 ).
486
The permutation plots helped to assess the validity of the PLS model by assessing the 487 risk of invalidity and verifying that the model does not only fit the current data set, but 488 also predicts Y from new observations.
510
The initial model that evaluated the zeta potential as a response, showed an excellent 511 model validity with its respective permutation plot (Fig. 6A) , confirming that the 512 response zeta potential can be modelled and described by PLS methods. Models for 513 the responses spleen proliferation, INF-γ, IL-2 and IL-6 showed excellent permutation 514 plots ( Fig. 6 B, C, D, E) , confirming the validity of the PLS model and predictions made 515 from selected responses. Validation for the variables IgG, IgG1, IgG2b, IL-5 and IL10 516 failed (plots not shown), confirming the previous invalidity of the models as already 517 seen in initial model evaluation (Figure 4 A and B ). Furthermore, this confirms that the 518 initially detected higher level of noise present for IL-5, IL-10 and IgG2b resulted in a 519 non-valid model, exemplifying that any predictions made using MVA depend on 520 verifying the validity of the models by the permutation testing.
522
Nevertheless, interpretations should be made in consideration of the assay accuracy, 523 which might lead to a higher level of noise in the data set, as seen for the variables 524 IgG2b, IL-5 and IL-10. Although clear trends and clusters were visible, interpretation 525 always depends on the accuracy of the assay. Furthermore, wider formulation profiling 526 is required to challenge this use of MVA in more complex vaccine adjuvant studies.
527
However, results here emphasize the use of multivariate analysis as a new tool for in-528 vivo vaccine efficacy correlations and cluster analysis for Th1 specific immune 529 responses.
531
This study shows that useful clustering, trends and predictions can be made using 532 MVA tools when a range of factors are varied (in this case DDA, TDB and DSPC 533 content which results in variations in vesicle size and zeta potential). Correlating in-534 vivo data may be a cost effective way for initial information about vaccine efficiency.
535
Information extracted from MVA may speed up the drug and process development 536 process, as desired in-vivo immune response targets might be predicted and are 537 dictated by the characteristics of the adjuvant or delivery system. From the present 16 study evaluations, the extraction of information from in-vivo data by partial least square 539 regression models gives a powerful tool to further characterize a vaccine formulation.
540
It can be used for initial clustering of in-vivo specific immune responses and help to 541 allow for future predictions of vaccine efficiency; overall, a new and useful method to 542 speed up the development process of a vaccine candidate.
544
MVA is a useful tool for not only summarizing and visualizing data sets, it also allows 545 for classification and identification of quantitative relationships between variables [12].
546
Matrices can be of alterable amounts of variables and observations, allowing for 547 flexibility in generating the data set. The application of those mathematical and 548 statistical tools is highly applicable for determination of relationships between various 549 measurements derived from a system or process [25] . We define the relationship 550 between two properties, where the effect of one property that can easily be measured 551 in the laboratory is related to the second property, which is more difficult to measure.
552
Initially, data of both property measurements are obtained, which are then built into a 553 model using multivariate regression, linking the dependent and independent variables.
555
The most significant advantage of using multivariate tools is the ability to analyse 556 multiple variables simultaneously, along with the reduction of the dimensionality of the 557 data set by projecting the data into a lower dimension thus improving data 558 interpretation and presentation [26] . Visualization and simplification of complex 559 pharmaceutical data is one of the main advantages of using MVA tools, and it is highly 560 applicable in pharmaceutical research and process or product development [27] . MVA 561 is furthermore often applied in diagnostics tools, where the identification of the major 562 contributing variables leads to the isolation of the deviation, frequently applied in 563 industrial processes for product quality control [26] .
565
Conclusion
566
In conclusion, models were developed to cluster and predict Th1 immune responses 567 to the vaccine formulation dependent on liposomal adjuvant characteristics.
568
Substitution of DDA:TDB with DSPC reduced the cationic zeta potential and resulted 569 in variations in vesicle size. The extent of DSPC incorporation correlated to polarised 570 immune responses with a combination of cellular and humoral immunity. We have 571 shown that the use of multivariate tools allows for clustering and predictions from key 572 liposome characteristics to specific in-vivo immune responses. The reliability of derived 573 PLS models suggests its general usefulness for predicting in-vivo specific immune 574 responses from offline measurements. Such multivariate approaches may be useful in 575 correlating key characteristics to critical quality attributes of a vaccine formulation.
17
Specific variable-dependences and independences support the selection of key 577 variables that need to be further optimized in a development process. Such methods 578 may be particularly useful for screening many variables at a time, especially in early 579 stage development processes. 580 581
